Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia.

Preeclampsia (PE) complicates ∼5% of human pregnancies and is one of the leading causes of pregnancy-related maternal deaths. The only definitive treatment, induced delivery, invariably results in prematurity, and in severe early-onset cases may lead to fetal death. Many currently available antihypertensive drugs are teratogenic and therefore precluded from use. Nonteratogenic antihypertensives help control maternal blood pressure in PE, but results in preventing preterm delivery and correcting fetal growth restriction (FGR) that also occurs in PE have been disappointing. Here we show that dietary nicotinamide, a nonteratogenic amide of vitamin B3, improves the maternal condition, prolongs pregnancies, and prevents FGR in two contrasting mouse models of PE. The first is caused by endotheliosis due to excess levels in the mothers of a soluble form of the receptor for vascular endothelial growth factor (VEGF), which binds to and inactivates VEGF. The second is caused by genetic absence of Ankiryn-repeat-and-SOCS-box-containing-protein 4, a factor that contributes to the differentiation of trophoblast stem cells into the giant trophoblast cells necessary for embryo implantation in mice; its absence leads to impaired placental development. In both models, fetal production of ATP is impaired and FGR is observed. We show here that nicotinamide decreases blood pressure and endotheliosis in the mothers, probably by inhibiting ADP ribosyl cyclase (ADPRC), and prevents FGR, probably by normalizing fetal ATP synthesis via the nucleotide salvage pathway. Because nicotinamide benefits both dams and pups, it merits evaluation for preventing or treating PE in humans.

Association between in utero zidovudine exposure and nondefect adverse birth outcomes: analysis of prospectively collected data from the Antiretroviral Pregnancy Registry.

OBJECTIVE: To examine the association between nondefect adverse birth outcomes and in utero exposure to zidovudine (ZDV)-containing regimens versus non-ZDV antiretroviral (ARV) regimens. DESIGN: Analysis of prospectively-collected data. SETTING: Global. POPULATION: HIV-infected pregnant women prenatally exposed to antiretrovirals. METHODS: Estimation of prevalence of and risk for nondefect adverse birth outcomes among HIV-infected women. MAIN OUTCOME MEASURES: Prevalence of and risk for nondefect adverse birth outcomes. RESULTS: Among 12 780 singleton birth outcomes with in utero ZDV exposure, 96.1% were live births; 3.9% were spontaneous abortions, induced abortions or stillbirths. Among live births, 16.4% were low birthweight (LBW); 12.3% were premature. Among 1904 outcomes with in utero exposure to non-ZDV ARV regimens, 85.8% were live births; 14.2% were spontaneous abortions, induced abortions or stillbirths. Among live births, 14.1% were LBW; 12.4% were premature. Relative risk comparing exposure to ZDV-containing ARV regimens to non-ZDV ARV regimens for spontaneous abortions was 0.18 (95% confidence interval [95% CI] 0.14-0.22); induced abortions 0.28 (95% CI 0.22-0.36); stillbirths 0.76 (95% CI 0.51-1.12); premature births 1.00 (95% CI 0.87-1.15) and LBW 1.17 (95% CI 1.02-1.33). CONCLUSION: Prevalence of nondefect adverse birth outcomes is lower among outcomes with in utero ZDV exposure versus in utero non-ZDV ARV exposure. The risks for spontaneous and induced abortions were no different for ZDV-containing regimens versus non-ZDV ARV regimens. For premature births and stillbirths, there was no significant difference in risk between the two regimens. The risk of LBW was statistically significantly higher among ZDV-containing regimens versus non-ZDV ARV regimens. TWEETABLE ABSTRACT: ZDV-containing regimens do not increase the risk for nondefect adverse birth outcomes.

Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.

According to the Institute of Medicine (IOM) Committee on the Assessment of the U.S. Drug Safety System, "The recent highly publicized controversies surrounding the safety of some drugs have contributed to a public perception that the drug safety system is in crisis. It seems fair to say that this perception has created an opportunity for a thorough evaluation of the U.S. drug safety system." The evaluation was focused on the U.S. Food and Drug Administration (FDA). To improve the FDA and its function in the public health system to improve therapeutics, it is critical to understand the contributions of other components.

Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study.

An observational surveillance study was conducted to monitor the safety and effectiveness of treatment with Digoxin Immune Fab (Ovine) (Digibind) in patients with digitalis intoxication. Before April 1986, a relatively limited number of patients received treatment with digoxin-specific Fab fragments through a multicenter clinical trial. Beginning with commercial availability in July 1986, this study sought additional, voluntarily reported clinical data pertaining to treatment through a 3 week follow-up. The study included 717 adults who received Digoxin Immune Fab (Ovine). Most patients were greater than or equal to 70 years old and developed toxicity during maintenance dosing with digoxin. Fifty percent of patients were reported to have a complete response to treatment, 24% a partial response and 12% no response. The response for 14% of patients was not reported or reported as uncertain. Six patients (0.8%, 95% confidence interval 0.3% to 1.8%) had an allergic reaction to digoxin-specific antibody fragments. Three of the six had a history of allergy to antibiotic drugs. Twenty patients (2.8%, 95% confidence interval 1.7% to 4.3%) developed recrudescent toxicity. Risk of recrudescent toxicity increased sixfold when less than 50% of the estimated dose of antibody was administered. A total of 215 patients experienced posttreatment adverse events. The events for 163 patients (76%) were judged to result from manifestations of underlying disease and thus considered unrelated to Fab treatment. Digoxin-specific antibody fragments were generally well tolerated and clinically effective in patients judged by treating physicians to have potentially life-threatening digitalis intoxication.

Monitoring the safety of antivirals. The example of the acyclovir experience.

The obligation to monitor the safety of newly introduced medicines is as old as the medical epidemiologic obligations of medicine itself. But society's expectations, the resources and methodologies for such monitoring, and the practices of the pharmacologic community have all evolved rapidly over the past decade. This report describes an extensive program of scientific epidemiologic monitoring of the safety of acyclovir during the first five years following approval. The presentation highlights the emerging field of pharmacoepidemiology, describes new and important resources and approaches for investigators concerned about drug safety monitoring, and presents safety data from the first five years of monitoring. The data thus far provide no reason for new safety concerns regarding this important antiviral; however, it is cautioned that, as in all such areas of public health protection, continued vigilance is needed.

Pharmaco-epidemiology--drugs, arthritis, and neoplasms: industry contribution to the data.

The real possibility that exogenous chemicals, including pharmaceuticals, increase risk of cancer is not a surprise. Epidemiologic systems to monitor exposure, as well as risk with or without such exposure, have been very hard to develop and very expensive to implement, and often have yielded ambiguous or questionably useful findings. The pharmaceutical industry is rising to the challenge of this situation, with attention to epidemiologic responsibilities and potential contributions deriving from them. This paper reviews the overall methodologic and public policy context surrounding pharmaco-epidemiology in the 1980s and then depicts an evolving program in pharmaco-epidemiology at one company, Burroughs Wellcome, as an example of one possible contributor. It discusses the company's epidemiologic approach to the question of association between treatment with disease-modifying antirheumatic drugs, one of which is manufactured by Burroughs Wellcome Company (Imuran brand azathioprine) and a possible increased risk of neoplasms in patients receiving these drugs as treatment for their rheumatoid arthritis. The paper will highlight specific epidemiologic applications of data bases derived from the published literature as well as voluntary reporting to industry. It will describe a proactive program in the development and conduct of epidemiologic studies to address these difficult problems.

Acyclovir in Pregnancy Registry. An observational epidemiologic approach.

Observational epidemiologic methods are being used to evaluate the safety of acyclovir in pregnancy. An essential component of this research is the establishment of a baseline expectation of pregnancy outcomes among women with herpes not receiving acyclovir. Continuing studies will be described in this report. To supplement these structured studies, an international case registration study was established. Through the Acyclovir in Pregnancy Registry, all cases of reported prenatal exposures to acyclovir are tracked to ascertain maternal exposure, risk factor, and pregnancy outcome information. The reports originate in all countries where oral acyclovir is marketed; data consolidation and analysis are coordinated at Burroughs Wellcome Co. with the assistance of a government/industry advisory panel. This presentation summarizes provisional data from the prospective reports, including trimester of exposure and reported outcomes of pregnancy. The total number of monitored pregnancies remains too small to support conclusions about the safety of acyclovir during pregnancy at this point. The potential for the registry and other epidemiologic studies to address the safety-in-pregnancy question will be discussed.

Possible brainstem involvement in the modification of thermoregulatory processes by chlordecone in rats.

The involvement of the central nervous system in the hypothermia induced by chlordecone was studied by evaluating the effects of infusions of chlordecone injected into the lateral and third ventricles and the cisterna magna on colonic temperature (Tcol). Compared to rats given vehicle, infusions of 40, 320 or 800 micrograms of chlordecone into the lateral ventricle or 320 or 800 micrograms of chlordecone into the third ventricle, through chronic indwelling cannulae, did not change significantly Tcol. However, intracisternal infusions of 80, 160, 320 or 800 micrograms of chlordecone produced significant hypothermia (maximally 2.2 degrees C) which persisted for as long as 6 hr. Intracisternal infusions of chlordecone also produced a rapid increase in the temperature of the tail skin (Tsk) which persisted throughout the period of hypothermia. This suggests that the hypothermia produced by central administration of chlordecone is related to peripheral vasodilation. Since chlordecone has been reported to induce release of NE in the brainstem, and NE is known to modulate tonic vasomotor control in the medulla, the effects of NE infused intracisternally were studied. Intracisternal infusions of NE (16 micrograms) significantly decreased Tcol and increased Tsk, supporting the hypothesis that hypothermia induced by chlordecone is associated with vasodilatory effects, mediated by an adrenergic mechanism in the brainstem.

Pharmacological evaluation of central adrenergic involvement in chlordecone-induced hypothermia.

Adrenergic involvement in the hypothermia produced by systemically administered chlordecone (CLD) was evaluated in the rat using intracisternal pretreatment with 6-hydroxydopamine (6-OHDA), alpha-adrenergic receptor antagonists (phenoxybenzamine and phentolamine) and beta-adrenergic antagonists (propranolol and atenolol). The effect of intraperitoneal administration of 75 mg/kg of chlordecone on colonic temperature (Tcol) in male Fischer-344 rats was measured 7 days after administration of 6-OHDA and 30 min following pretreatment with the receptor antagonists. Prior depletion of catecholamines in brain with 250 micrograms of 6-OHDA administered intracerebrally attenuated hypothermia induced by chlordecone, without affecting basal Tcol. Phenoxybenzamine (10 or 20 micrograms) and phentolamine (5 or 10 micrograms) also reduced the hypothermic response to chlordecone. The beta-adrenergic receptor antagonists propranolol (50 or 100 micrograms) and atenolol (10 or 20 micrograms) did not attenuate chlordecone-induced hypothermia. These data suggest that the hypothermia induced by chlordecone is a result of alterations in central alpha-adrenergic functions, possibly involved with the sympathetic control of vasomotor tone.

Colchicine administered into the area of the nucleus basalis decreases cortical nicotinic cholinergic receptors labelled by [3H]-acetylcholine.

Lesions in the nucleus basalis in the rat are known to decrease presynaptic markers for acetylcholine, including levels of cholineacetyltransferase (CHAT), high affinity uptake of choline and levels of acetylcholinesterase. Effects of lesions of the nucleus basalis on populations of nicotinic and muscarinic receptors are less well understood. After bilateral injection of the neurotoxic agent, colchicine into the nucleus basalis in the rat, levels of CHAT in the cerebral cortex were reduced 44%. Muscarinic cholinergic [( 3H]QNB) and dopaminergic [( 3H]spiroperidol) binding was not changed in the cortex, hippocampus or striatum. However, significant decreases in nicotinic binding sites, labelled by [( 3H]acetylcholine), were observed in the frontal cortex of nucleus basalis treated animals; scatchard plot analysis indicated a significant decrease in the number, but not affinity, of nicotinic binding sites. Colchicine injected into the nucleus basalis had no effect on the binding of [3H]acetylcholine in the hippocampus, but decreased binding of [3H]acetylcholine in the striatum. Subsequent experiments, in which colchicine was administered into the striatum at a site above the nucleus basalis had no significant effect on nicotinic binding in the striatum or frontal cortex. These results support the hypothesis that degeneration of the nucleus-basalis-cortical cholinergic pathway results in a loss of presynaptic nicotinic binding sites in the cortex as well as in the striatum (through transsynaptic degeneration of the cortico-striatal pathway).

Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes.

A series of 2-amino-1-(4-substituted-2,5-dimethoxyphenyl)butanes (Table V) was prepared as analogues of (R)-2-amino-1-(2,5-dimethoxy-4-methylphenyl)butane (1a). 1-(2,5-Dimethoxyphenyl)-2-(N-phthalimido)butane (7) was utilized as a synthetic intermediate common to many of the target compounds. Animal data are presented indicating that most of these analogues have low hallucinogenic potential. Selected compounds were compared with 1a in an avoidance-response acquisition model which differentiates between 1a and the human hallucinogens DOM (2a) and DOET (2b). Structure-activity relationships of these analogues are discussed.

Trimethyltin increases interleukin (IL)-1 alpha, IL-6 and tumor necrosis factor alpha mRNA levels in rat hippocampus.

Within the central nervous system (CNS), cytokines are though to have active roles in pathophysiological changes seen in various neurological diseases and trauma. The present study was undertaken to examine the early response of pro-inflammatory cytokines following exposure to a specific neurotoxicant (trimethyltin; TMT). mRNA levels for interleukin (IL)-1 alpha, IL-1 beta, IL-6 and tumor necrosis factor (TNF) alpha were measured in the hippocampus of adult male Long-Evans hooded rats following an acute injection of trimethyltin hydroxide (8 mg TMT/kg body weight). At various times following exposure (6 h to 8 days), hippocampal tissues were excised and relative changes in cytokine mRNA levels were assessed by reverse transcription and polymerase chain reaction. IL-1 alpha, IL-6 and TNF alpha mRNA levels in the hippocampus increased within 6 h and remained elevated for 8 days. Quantitative analysis of mRNA transcripts revealed a two-fold increase in both IL-6 and TNF alpha within 6 h and a continued elevation of TNF alpha to 9-fold by 12 h. Within 96 h, glial fibrillary acidic protein (GFAP) mRNA levels were elevated in the hippocampus. Histological examination showed sparse individual neuronal necrosis at this time in both the pyramidal and granule cell regions with no increase in astrocyte GFAP immunoreactivity. However, an early, 24 h, response of microglial cells was indicated by increased lectin binding. This morphological profile progressed over time to a profound neuronal loss in the CA3-4 granule cell layer and marked astrocyte hypertrophy. The onset of pro-inflammatory cytokine mRNA expression appears to be temporally associated with histological evidence of elevated microglia in the hippocampus. It is proposed that microglia and pro-inflammatory cytokines play a modulatory role in the early stages of TMT-induced neurotoxicity.

Differential patterns of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 mRNA and protein levels in developing regions of rat brain.

The present studies were undertaken to characterize the regional and temporal patterns of neurotrophin messenger RNA and protein levels for beta-nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 in the developing CNS. We have examined the levels of these neurotrophin messenger RNAs with ribonuclease protection assays and corresponding protein levels with enzyme-linked immunosorbent assays in the developing Long-Evans rat hippocampus, neocortex and cerebellum on postnatal days 1, 7, 14, 21, and 92. In addition, immunohistochemistry was used to localize the neurotrophins in these developing brain regions. Results indicated that in neocortex and hippocampus, messenger RNA for both nerve growth factor and brain-derived neurotrophic factor increased in an age-dependent manner, reaching a plateau by postnatal day 14. In the neocortex, nerve growth factor and brain-derived neurotrophic factor protein levels both peaked at postnatal day 14. In hippocampus, nerve growth factor protein peaked at postnatal day 7 while brain-derived neurotrophic factor peaked at postnatal day 14. In cerebellum, nerve growth factor messenger RNA levels were flat, while nerve growth factor protein peaked at postnatal day 7. Brain-derived neurotrophic factor messenger RNA increased in an age-dependent manner while the pattern for its protein levels was mixed. Neurotrophin-3 messeger RNA levels increased in an age-dependent manner in hippocampus, peaked at postnatal day14 in cerebellum, and no changes occurred in neocortex. Neurotrophin-3 protein was at its peak at postnatal day 1 and thereafter decreased at other postnatal days in all three brain regions. Results of neurotrophin immunohistochemistry often paralleled and complemented enzyme-linked immunosorbent assay data, demonstrating specific cell groups containing neurotrophin proteins in these regions. Within each region, patterns with regard to messenger RNA and respective protein levels for each neurotrophin were unique. No consistent relationship between patterns of neurotrophin messenger RNAs and their cognate proteins was observed between regions. The different regional patterns for neurotrophin messengerRNA and protein levels in each brain region indicate that messenger RNA studies of neurotrophin messenger RNA must be augmented by protein determination to fully characterize spatial and temporal neurotrophin distribution.

Mechanisms underlying AlCl3 inhibition of agonist-stimulated inositol phosphate accumulation. Role of calcium, G-proteins, phospholipase C and protein kinase C.

Possible mechanisms of AlCl3-induced inhibition of agonist-stimulated inositol phosphate (IP) accumulation were investigated using rat brain cortex slices, synaptosomes or homogenates. Under conditions in which AlCl3 inhibits carbachol (CARB)-stimulated IP accumulation (Gp-mediated), AlCl3 did not affect CARB (100 microM)-induced decreases (Gi-mediated) in 30 microM forskolin-stimulated cAMP accumulation, suggesting that AlCl3 may be specific for Gp-mediated signal transduction. To determine whether AlCl3 interfered with Gp function and/or phosphatidylinositol-specific phospholipase C (PiPLC) activity, effects of AlCl3 on CARB- and Ca(2+)-stimulated IP accumulation were examined in cortical synaptosomes. AlCl3 (500 microM) decreased CARB (1 mM)- and Ca2+ (20 microM ionomycin)-stimulated IP accumulation to 77 and 75% of control, respectively, suggesting that AlCl3 may not directly affect Gp activity, but does inhibit PiPLC activity. In cortical homogenates, AlCl3 (10-500 microM) inhibited hydrolysis of [3H]phosphatidylinositol 4,5-bisphosphate (PIP2) by PiPLC in a concentration-dependent manner with an estimated IC50 of 100 microM. The effects of AlCl3 on modulation of IP accumulation by extracellular Ca2+ and PKC were also examined as potential mechanisms. Decreasing the extracellular Ca2+ concentration ([Ca2+]e) from 1.0 to 0.1 mM decreased CARB-stimulated IP accumulation in slices. AlCl3 (500 microM) decreased significantly 1 mM CARB-stimulated IP accumulation in 1.0 and 0.1 mM Ca2+ solutions; however, the effect of AlCl3 on IP accumulation did not depend on [Ca2+]e. In cortical slices, inhibition of 1 mM CARB-stimulated IP accumulation by 500 microM AlCl3 was not altered by the PKC activator phorbol 12,13-dibutyrate (PdBu, 1 microM), or the PKC inhibitor H-7 (10 microM), suggesting that AlCl3 does not interfere with IP accumulation by activation of PKC. Other studies found that AlCl3 (10-100 microM) inhibited PKC activity in a concentration-dependent manner in both cytosolic and membrane fractions of cortical homogenates with an estimated IC50 of 60 microM. These results support the hypothesis that AlCl3 inhibition of agonist-stimulated IP accumulation may be mediated by inhibition of PiPLC activity, rather than disruption of G-protein function or modulation of the IP signalling system by Ca2+ or PKC.

Major advances in international pharmacoepidemiology.

Pharmacoepidemiology applies the principles of epidemiology to the problems of pharmacotherapy--particularly addressing society's need to know more about drug safety issues than the highly structured pre-approval clinical trials programs can provide. Thus, the concerns are truly international, and the approaches must also be international, tempered by the ability to generalize from one nation's experience, and by the availability of specialized research resources. Studying the impact of medical and medicinal interventions, the field is especially well-served by the major advances in computer system's support of medical settings and the multipurpose linked automated data base, linking automated pharmacy-dispensing data with same-population automated hospital discharge and other medical and demographic data. The development of such resources, the direction of their fruits to complement the hard work of hands-on traditional epidemiologic approaches in this field, the recruitment and support of trained researchers in the field, and the international coordination of policy and practice realistic to the capacity while responsive to the demand are all among the exciting challenges ahead.

New horizons: future directions in neurotoxicology.

Neurotoxicology is a relatively young discipline that has undergone significant growth during the last 25 years. During the late 1970s and 1980s, numerous national and international conferences and meetings were devoted to the topic of neurotoxicology, the formation of societies or specialty sections related to neurotoxicology, and the establishment of two independent peer-reviewed journals devoted to neurotoxicology. This decade was also associated with a rapid increase in our knowledge of chemical effects on the structure and function of the nervous system. During the 1990s, regulatory agencies such as the U.S. Environmental Protection Agency accepted neurotoxicology as a crucial end point and neurotoxicity testing and risk assessment guidelines were published. Neurotoxicology has also been accepted at the international level as evidenced by environmental criteria documents published by the International Programme on Chemical Safety and testing guidelines by the Organization of Economic Cooperation and Development. In recent years, there has been increased concern that the etiology of some neurodegenerative diseases may be associated with exposure to neurotoxic agents and that subpopulations of humans such as children and the elderly may be differentially sensitive to neurotoxic exposure. In the future, mechanistic information derived from basic research will be used in the identification and characterization of chemicals with neurotoxic potential.

The concern for developmental neurotoxicology: is it justified and what is being done about it?

In general, it is believed that the possibility of an adverse developmental outcome following conception is relatively high. In most cases, the cause of the defect is not clear, although exposure to chemical agents at a critical period during development has been proposed to play a significant role. Consequently, regulatory agencies such as the U.S. Environmental Protection Agency (U.S. EPA) have promulgated testing guidelines for assessing developmental neurotoxicity of chemicals in animal testing protocols. Concerns have been expressed about the use of behavioral tests to evaluate chemicals for developmental neurotoxicity, since some investigators believe that they lack predictive validity for human developmental neurotoxicity. Other investigators have indicated that results from such studies are difficult to interpret because of a lack of standardization and sensitivity of the tests. Furthermore, it has been argued that the developing organism is not especially sensitive to chemicals or, if effects are observed, the developing organism is capable of compensating for the deficit. Recent research, however, has adequately demonstrated that developing organisms are especially vulnerable to chemical agents if the exposure occurs at a critical period during development, while other studies have supported the assumption that functional or behavioral effects observed in animal models can be extrapolated to humans. These findings support the routine assessment of chemicals for developmental neurotoxicity using functional end points and suggest that currently available methods could be used to determine more precisely the mechanism of chemical-induced developmental defects.

Developmental neurotoxicology of endocrine disruptors and pesticides: identification of information gaps and research needs.

There is increasing evidence that some environmental chemicals can interrupt neurodevelopmental processes during critical periods of development, resulting in effects on sensory, motor, and cognitive function. It is now generally accepted that developing organisms are differentially sensitive to chemical exposure because of toxicokinetic and/or toxicodynamic factors. Regulatory mechanisms have been implemented to protect humans from over- or inappropriate exposures to environmental chemicals. Current regulatory practices, however, may be insufficient because of the possibility that some environmental chemicals interfere with endocrine function at key periods of neurodevelopment. In addition, a recent National Research Council (NRC) report on pesticide contamination in the diets of infants and children concluded that current regulatory practices may not sufficiently protect infants and children from the risk of pesticide exposure. The NRC report indicates that regulatory agencies might underestimate the actual exposure of infants and children to pesticides and rely too heavily on data from adults in the risk assessment of pesticides. Consideration of endocrine-disrupting chemicals and the differential susceptibility of infants and children has led to identification of a number of information gaps and research needs that should be addressed in order to improve future risk assessments for these chemicals.

Strategy for the assessment of neurobehavioral consequences of environmental factors.

One of the critical issues confronting the evolving discipline of behavioral and neurological toxicology is the general lack of test validation in animal models. This paper seeks to provide a strategy aimed at resolving this important problem. It is proposed that test validation be accomplished by evaluating known neurotoxins in a battery of tests chosen to assess in animal models a wide range of effects on the basis of reported human toxicosis symptomatology. We propose to measure ongoing home cage motor activity, food consumption, water consumption, clay consumption (and the diurnal cycling of these), neurological/physiological indices (reflexes, autonomic signs, equilibrium/gait, balance, tremor, reactivity, and muscular strength), and aspects of cognitive and associative behavior involving both endogenous and exogenous (sensory) control of responding. An integrated, time-efficient scheme, covering 90 days of chemical treatment and 30 days of post-dosing recovery will be used. Chemical substances to be evaluated were chosen with the view of representing classes of neurotoxic effects. For initial study, triethyltin was chosen as an agent producing demyelination of nerves, acrylamide as an agent producing "dying-back" neuropathy, and methylmercury as an agent producing mixed central and peripheral neuropathies. Agents which attack specific loci in the nervous system and those producing anoxia will not be assessed in the first stages of this research due to lack of species generality of known effects, present lack of appropriate exposure facilities, or other problems. In addition, two drugs (amphetamine and sodium salicylate) will be investigated to support the generality of the testing procedures. By comparing the observed results of the neurotoxins in the animal models with the predicted effects based on reported human symptomatology, some decision concerning the validity of each procedure will be made. It is expected that the validation of tests to be used in behavioral and neurological toxicology will permit the meaningful assessment of more complex issues, such as the mechanisms by which neurotoxins act.

Risk assessment for neurobehavioral toxicity: SGOMSEC joint report.

Behavioral end points for neurotoxicity risk assessment have been developed and examined over the past three decades. They are now ready to move from simple qualitative guidelines, such as exemplified by reference doses, to more quantitative models, such as benchmark doses, based on dose-response information. Risk assessors, confronted by a wider array of methodologies and data than in the past, should be offered guidance in interpretation because now they have to deal with unaccustomed questions and problems. These include reversibility, susceptible populations, multiple end points, and the details of dose-response and dose-effect distributions.